Publication:
Prevalence of human papillomavirus genotypes in cervical cancer

dc.contributor.authorChinchai T.
dc.contributor.authorChansaenroj J.
dc.contributor.authorSwangvaree S.
dc.contributor.authorJunyangdikul P.
dc.contributor.authorPoovorawan Y.
dc.date.accessioned2021-04-05T03:34:07Z
dc.date.available2021-04-05T03:34:07Z
dc.date.issued2012
dc.date.issuedBE2555
dc.description.abstractBackground and Objective: Cervical cancer is the second most common female genital cancer worldwide. There is strong epidemiological and molecular evidence indicating that human papillomavirus (HPV) infection is a necessary event in the development of cervical intraepithelial lesion and subsequent invasive carcinoma. The aim of this study was to investigate the HPV genotype distribution and prevalence in cervical cancer of Thai women. Materials and Methods: One hundred fifty-five cervical cancer specimens were enrolled in this study. The HPV genotypes were determined by means of the combined use of a line probe assay (INNO-LiPA) and DNA chip methods. Results: Of the overall prevalence of HPV in the study group, 83.2% and 11.6% of the cases had single and multiple genotype infections, respectively. The most prevalent genotypes were HPV 16 (51%), followed by HPV 18 (20%), HPV 52 (10.3%), HPV 58 (5.8%), and HPV 33 (4.5%). All HPV genotypes found in this study could be classified as 13 highrisk HPV, 2 low-risk HPV, and 2 additional types. Of the specimens, 94.8% had at least one high-risk HPV genotype infection. Conclusion: As for the potential benefits of commercially available prophylactic vaccines to prevent HPV infection in Thailand, both vaccines (bivalent and quadrivalent) can protect from HPV-related cervical cancer in only approximately 71%. Therefore, screening programs such as routine Papanicolaou test, cytology, and HPV DNA detection are still essential for cervical cancer prevention. Moreover, future generations of HPV vaccines should also include the other most common genotypes and decrease the severe adverse effects reported at the present time. Copyright © 2012 by IGCS and ESGO.
dc.format.mimetypeapplication/pdf
dc.identifier.citationInternational Journal of Gynecological Cancer. Vol 22, No.6 (2012), p.1063-1068
dc.identifier.doi10.1097/IGC.0b013e318259d904
dc.identifier.issn1048891X
dc.identifier.other2-s2.0-84863628026
dc.identifier.urihttps://hdl.handle.net/20.500.14740/7021
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherVirus DNA
dc.subject.otherAdult
dc.subject.otherAged
dc.subject.otherArticle
dc.subject.otherCancer prevention
dc.subject.otherCancer staging
dc.subject.otherCytology
dc.subject.otherDNA microarray
dc.subject.otherFemale
dc.subject.otherGenotype
dc.subject.otherHuman
dc.subject.otherHuman papillomavirus type 16
dc.subject.otherHuman papillomavirus type 18
dc.subject.otherHuman papillomavirus type 33
dc.subject.otherHuman papillomavirus type 52
dc.subject.otherHuman papillomavirus type 58
dc.subject.otherMajor clinical study
dc.subject.otherNonhuman
dc.subject.otherPapanicolaou test
dc.subject.otherPrevalence
dc.subject.otherPriority journal
dc.subject.otherThailand
dc.subject.otherUterine cervix cancer
dc.subject.otherVerruca vulgaris
dc.subject.otherWart virus
dc.subject.otherAdult
dc.subject.otherAged
dc.subject.otherAged, 80 and over
dc.subject.otherAlphapapillomavirus
dc.subject.otherFemale
dc.subject.otherGenotyping Techniques
dc.subject.otherHumans
dc.subject.otherMiddle Aged
dc.subject.otherPapillomavirus Infections
dc.subject.otherThailand
dc.subject.otherUterine Cervical Neoplasms
dc.titlePrevalence of human papillomavirus genotypes in cervical cancer
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84863628026&doi=10.1097%2fIGC.0b013e318259d904&partnerID=40&md5=cf0450db22da58f7f09fd4cd224143e6

Files